Topic: Biology

Scientists have developed a new virus therapy that can help fight brain cancer. The therapy uses a genetically engineered virus to target and kill cancer cells in the brain. In a clinical trial, patients who received this treatment had longer survival rates compared to historical outcomes.

This virus therapy is designed to supercharge the immune system against brain cancer. Researchers from Mass General Brigham and Dana-Farber Cancer Institute found that a single dose of this oncolytic virus can bring immune cells deep into brain tumors and keep them active there.

The therapy uses an engineered herpes simplex virus that replicates only inside glioblastoma cells, leaving healthy tissue unaffected. Once inside a tumor cell, the virus destroys it and then produces copies of itself that move on to infect neighboring cancer cells.

In a phase 1 clinical trial involving 41 patients with recurrent glioblastoma, treatment with this virus was associated with longer survival compared to historical outcomes. The strongest benefit was seen in patients who already had antibodies against the virus.

To better understand how the therapy works, researchers analyzed tumor samples from trial participants. They found that the treatment led to a sustained presence of immune T cells within the tumors. Patients whose cytotoxic T cells were located closer to dying tumor cells tended to survive longer after treatment.

The therapy also boosted the number of existing T cells in the brain, suggesting that it strengthens the body's own immune defenses rather than relying solely on new immune activity.

Why It Matters

This breakthrough could lead to a new standard of care for patients with glioblastoma, a type of brain cancer that has not benefited from immunotherapies as much as other types. It also highlights the potential of innovative therapies in fighting cancer.

Key Facts

• A single dose of this oncolytic virus can bring immune cells deep into brain tumors and keep them active there.
• The therapy uses an engineered herpes simplex virus that replicates only inside glioblastoma cells, leaving healthy tissue unaffected.
• In a phase 1 clinical trial involving 41 patients with recurrent glioblastoma, treatment with this virus was associated with longer survival compared to historical outcomes.
• Patients whose cytotoxic T cells were located closer to dying tumor cells tended to survive longer after treatment.
• The therapy also boosted the number of existing T cells in the brain, suggesting that it strengthens the body's own immune defenses.

Key Terms

Oncolytic virus

A genetically engineered virus designed to infect and kill cancer cells.

Implications

This breakthrough could lead to a new standard of care for patients with glioblastoma, a type of brain cancer that has not benefited from immunotherapies as much as other types. It also highlights the potential of innovative therapies in fighting cancer.